Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets

Publisher： Karger

E-ISSN： 1662-6575|9|2|285-289

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.9, Iss.2, 2016-05, pp. : 285-289

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

By  

Case Reports in Oncology, Vol. 9, Iss. 1, 2016-03 ,pp. : 171-176

Karger

Access to resources Recommend Favorite

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization

By  

Case Reports in Oncology, Vol. 9, Iss. 1, 2016-01 ,pp. : 62-67

Karger

Access to resources Recommend Favorite

Erlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung Disease

By  

Case Reports in Oncology, Vol. 4, Iss. 3, 2011-09 ,pp. : 464-466

Karger

Access to resources Recommend Favorite

Metabolic Response Assessment in Non-Small Cell Lung Cancer Patients after Platinum-Based Therapy: A Preliminary Analysis

By  

Current Medical Imaging Reviews, Vol. 11, Iss. 4, 2015-01 ,pp. : 218-227

Bentham Science Publishers

Access to resources Recommend Favorite

Bevacizumab in combination with different platinum‐based doublets in the first‐line treatment for advanced nonsquamous non‐small‐cell lung cancer: A network meta‐analysis

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 142, Iss. 8, 2018-04 ,pp. : 1676-1688

John Wiley & Sons Inc

Access to resources Recommend Favorite